Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Update

Cardiff Oncology, Inc. (NASDAQ:CRDF) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 7,320,000 shares, a growth of 7.2% from the September 30th total of 6,830,000 shares. Based on an average daily volume of 495,200 shares, the days-to-cover ratio is presently 14.8 days.

Institutional Investors Weigh In On Cardiff Oncology

Institutional investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. boosted its stake in shares of Cardiff Oncology by 380.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after buying an additional 962,940 shares during the last quarter. Blair William & Co. IL grew its stake in Cardiff Oncology by 32.4% in the first quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after purchasing an additional 42,180 shares in the last quarter. Vanguard Group Inc. raised its holdings in Cardiff Oncology by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock valued at $10,260,000 after acquiring an additional 9,468 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Cardiff Oncology during the second quarter worth approximately $27,000. Finally, Rhumbline Advisers acquired a new position in shares of Cardiff Oncology in the second quarter valued at approximately $102,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Stock Performance

CRDF traded up $0.08 during midday trading on Friday, hitting $3.20. The company had a trading volume of 599,377 shares, compared to its average volume of 929,981. Cardiff Oncology has a twelve month low of $0.94 and a twelve month high of $6.42. The firm’s 50-day simple moving average is $2.59 and its 200-day simple moving average is $2.82. The company has a market capitalization of $148.96 million, a PE ratio of -3.53 and a beta of 1.96.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.12 million. Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. During the same quarter last year, the firm earned ($0.25) EPS. As a group, sell-side analysts anticipate that Cardiff Oncology will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum initiated coverage on Cardiff Oncology in a research note on Friday, September 6th. They issued a “buy” rating and a $8.00 target price for the company.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.